Search results
Results from the WOW.Com Content Network
VIVUS has traded in a 52-week trading range of $9.86 to $31.21, and the consensus analyst price target from Thomson Reuters was $19.59 before the effects of today's earnings.
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
With a closing price of ₩82,100 on September 8, it appeared that a 200% valuation return was achieved. Studio Dragon had granted Choi 72,800 shares as stock options for being the first CEO of Studio Dragon in 2016. The first time Choi exercised stock options was in August 2019, when she exercised options for 21,840 shares.
For premium support please call: 800-290-4726 more ways to reach us